Antibiotics in myasthenia gravis: Thinking outside the black box
- PMID: 34089196
- DOI: 10.1002/mus.27346
Antibiotics in myasthenia gravis: Thinking outside the black box
Comment on
-
Pharmacosafety of fluoroquinolone and macrolide antibiotics in the clinical care of patients with myasthenia gravis.Muscle Nerve. 2021 Aug;64(2):156-162. doi: 10.1002/mus.27230. Epub 2021 Mar 26. Muscle Nerve. 2021. PMID: 33719062
References
REFERENCES
-
- FDA US Food and Drug Administration. MedWatch Online Voluntary Reporting Form. https://www.accessdata.fda.gov/scripts/medwatch/index.cfm. Accessed May 2, 2021.
-
- FDA US Food and Drug Administration. Reporting Serious Problems to FDA | FDA. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-e.... Accessed May 2, 2021.
-
- FDA US Food and Drug Administration. Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act | FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents.... Accessed May 2, 2021.
-
- Murphy S, Roberts R. “Black box” 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol. 2006;117(1):34-39. https://doi.org/10.1016/j.jaci.2005.10.031
-
- Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357(9274):2122-2128. https://doi.org/10.1016/S0140-6736(00)05186-2
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical